Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 68.1%

Neg 68.1% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.